{"name":"Viamet","slug":"viamet","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQOFZ4WGpaYWtFZ2VFZlo4Wk1LMEpUTkZEbWZTbzZYWW1RVFFtTlJZYVFmUU1JZEJFQ1NpdVB2TF80LTQ5Mm1iUUJEMkJJcWM4d3JSZ0k2VHZfNVFYYV9DU19Yd1F2Y091UElnV1JnWm96eTUzR0xubzAxYmFMaFZpXzNpckN1aHBzazR2V3JBR0RXQzhJN1A0WEs0Q2pDMGctdVE?oc=5","date":"2024-08-30","type":"trial","source":"Business North Carolina","summary":"Drug trial financier NovaQuest expands to startup investing. - Business North Carolina","headline":"Drug trial financier NovaQuest expands to startup investing.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOd2FPanc1T3VDanFzMHVTS3dIZThZOHgwVDNBd2xGOWY1UmF4UV9kTDlDanJ4ZTRMVDVocDJHR3FxSVhCTmxQMVlPb0VVMXA1aWhhSVNvaTIxSnBnWnVJVVhyekJneUwzUWZQT2VUT1Vib0tjejZnQnI4RXJiWjNiLWYxM080ZmtEaWp3NGVVNG05WkE1cFZvZTFCR29EOTkxNFhBeGJUQnFPakswalpRbTBYaFc?oc=5","date":"2020-02-03","type":"pipeline","source":"PharmaTimes","summary":"Blueberry Therapeutics appoints Dr Adrian Howd to board of directors - PharmaTimes","headline":"Blueberry Therapeutics appoints Dr Adrian Howd to board of directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPU3QxN3BHSjNkRlRzQnllVF9rYzZod0tzU21JNk50MjI4dEpFZWwzTFBGTG5Rd0F3bXhqVTJqRUJsQlg4TkNJX2ZtTmNlX0xzNE02b2s2UUJ2U21IYkFuTFhxNFh1WDFSaE1aV2lvdm5fMjZ0NF9fa01ITWc5WjNHb2IwVmVvVkFmeW9jaEp4cmsyOG5MOWdKYjQxckFzdzlFaVZqTGpRR24zb2ZCVVhYRUxaVkFSZGF5UUE?oc=5","date":"2018-12-11","type":"pipeline","source":"European Medical Journal","summary":"Are We Ready to Change the Course of Inflammatory Bowel Disease? - European Medical Journal","headline":"Are We Ready to Change the Course of Inflammatory Bowel Disease?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPT0RDbnhsNU5WRjZqRlpXWjJNYWlSRlRFemRFa21FbGZwUWJvNFdyaGFkQlgtY3M0d0NPUDFsOW83NWlGMGIwb3V3M3VEZjdQdC1SRVdzR1lrUDE2VzF2VG5yTWYzZWdxWGM3SnJoWGhrcnFtLWdCblNuVTNILXN1VFR3ZE0tREpZcnpZNU42UVF5V2c?oc=5","date":"2016-05-12","type":"pipeline","source":"Fierce Biotech","summary":"Second time unlucky for Viamet in topsy-turvy IPO week - Fierce Biotech","headline":"Second time unlucky for Viamet in topsy-turvy IPO week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVEN6WFRZLVByM2RyV0JMajFjTG1lV0l4VkpLdjI5UGVpTU9QdHI3d2lrU3dSd1EyZDhxNGpNY3VhZVRlVXUteGQzQWVzWEZueDJCcnJpT0Q1Y090SGVYYTRhVjVvUFp2b2pSWkVsRVBNUTN3dzdTdUlkeklVdmV4QUhPUkdpWXVyQkxyTm8xRU5DTjIzYjUwbWNRd0NsYUFaZmx0Zl9LVHpIZw?oc=5","date":"2016-05-04","type":"pipeline","source":"Fierce Biotech","summary":"Novartis-backed Viamet hopes for better luck with IPO - Fierce Biotech","headline":"Novartis-backed Viamet hopes for better luck with IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQbnZFa25tdUFiS3JqUEFNWENQdHF5WkdzeXlJcWNzY2xZYm5HTkhfenlrMjhhSU5TWkxjalE2N2ZNQ1JfcDI5dVNPYWxfYjdvQk1RV05VeU1FQy16YXpZeWhPWHdqbnF1UmpHdU1BUGtYaUNla3VoT2t0MnFPR2FCWmNqZEh0Vkg5bHFuMXZ6YW5qUkpYNDlHYW95ZWx0SUZ0U2Y5cjZORkRIUGdFUllzU1BocHctaGUzalNSUGxDTVhhYjBGcUhWQWRjLU84d1E?oc=5","date":"2014-10-22","type":"pipeline","source":"BioSpace","summary":"Viamet Pharmaceuticals Withdraws $75 Million IPO, Spins Off Cancer Program To Form Innocrin Pharmaceuticals - BioSpace","headline":"Viamet Pharmaceuticals Withdraws $75 Million IPO, Spins Off Cancer Program To Form Innocrin Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}